MedTrace Logo

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

NCT02278965 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2022-08-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether it is feasible to give a combination of Metformin and omega-3 fatty acids for one year to women with a history of early stage breast cancer. We will also evaluate whether the metformin and omega-3 fatty acids combination causes changes in breast tissue, blood, and mammograms.

Conditions

  • Stage 0 Breast Carcinoma
  • Breast Neoplasms
  • Stage I Breast Carcinoma
  • Stage II Breast Carcinoma
  • Stage III Breast Carcinoma

Interventions

DRUG

Metformin

Metformin 850mg, oral, twice a day for 12 months

DRUG

Omega-3 fatty acids

Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months

Sponsors & Collaborators

  • Katherine D. Crew

    lead OTHER

Principal Investigators

  • Katherine Crew, MD, MS · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-22
Primary Completion
2017-04-19
Completion
2017-04-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02278965 on ClinicalTrials.gov